MSU Drug Discovery Seminar - Jagadananda Ghosh, PhD

Development Of A New Therapy For Enzalutamide-

Resistant, Neuroendocrine Prostate Cancer.

When prostate cancer progresses beyond treatment with androgen receptor (AR) blockers, a spectrum of cell type emerges in the tumor microenvironment. Notably, the population of cells with neuroendocrine (NE) features is increased from its usual ~2% to >20% upon treatment with strong AR inhibitors, such as enzalutamide. Enzalutamide resistant NE type prostate cancer (ERPC-NE) is especially problematic because no effective therapy is currently available to effectively kill these cells, primarily due to the lack of knowledge about critical molecular targets. By gene expression array analysis using clinically relevant ERPC cell culture models, we identified a new therapeutic target called Tribbles 2 (Trib2), which appears to confer resistance to enzalutamide therapy by promoting lineage plasticity.  

Date:  Friday, March 25, 2022

Time:  09:00 AM

Location Zoom:  https://msu.zoom.us/j/99829704233

Passcode:  839433